TY - JOUR AU - Kotschy, A; Szlavik, Z; Murray, J; Davidson, J; Maragno, A L; Le Toumelin-Braizat, G; Chanrion, M; Kelly, G L; Gong, J N; Moujalled, D M; Bruno, A; Csekei, M; Paczal, A; Szabo, Z B; Sipos, S; Radics, G; Proszenyak, A; Balint, B; Ondi, L; Blasko, G; Robertson, A; Surgenor, A; Dokurno, P; Chen, I; Matassova, N; Smith, J; Pedder, C; Graham, C; Studeny, A; Lysiak-Auvity, G; Girard, A M; Gravé, F; Segal, D; Riffkin, C D; Pomilio, G; Galbraith, L C; Aubrey, B J; Brennan, M S; Herold, M J; Chang, C; Guasconi, G; Cauquil, N; Melchiore, F; Guigal-Stephan, N; Lockhart, B; Colland, F; Hickman, J A; Roberts, A W; Huang, D C; Wei, A H; Strasser, A; Lessene, G; Geneste, O TI - The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models JO - Nature VL - 538 PY - 2016 DO - 10.1038/nature19830 L3 - PubMed-ID: 27760111 SP - 477 EP - 482 ER -